Eli Lilly and Company, incorporated in 1901, is a global pharmaceutical company operating within a single business segment: human pharmaceutical products. The company focuses on the discovery, development, manufacture, and marketing of innovative medicines. Lilly's long-term success depends on its ability to discover, acquire, develop, and commercialize new medicines. The company's products are manufactured in facilities located in the U.S., Europe, and Asia, and are sold in approximately 105 countries.

Lilly's key competitive advantages include its strong research and development capabilities, a diverse product portfolio, and a global presence. The company faces competition from other large pharmaceutical companies, as well as generic and biosimilar manufacturers.

• Employees: 43,000 (as of December 31, 2023)
• Geographic Footprint: ~105 countries
• Headquarters: Indianapolis, Indiana
• Founded: 1876
• Number of locations/facilities: 22 (11 in the U.S. including Puerto Rico)
• Revenue: $34.1 billion (FY2023)
• Market Cap: $398.3 billion (as of Q2 2023)
• Key Subsidiaries/Brands: Loxo@Lilly, Lilly Bio-Medicines, Lilly Diabetes and Obesity

• CEO: David Ricks (since 2017)
• CFO: Anat Ashkenazi (since 2021)
• Board Chair: David Ricks
• Other Key Executives: Eric Dozier (Executive Vice President, Human Resources and Diversity), Anat Hakim (Executive Vice President, General Counsel and Secretary), Edgardo Hernandez (Executive Vice President and President, Manufacturing Operations), Patrik Jonsson (Executive Vice President and President, Lilly Diabetes and Obesity and President, Lilly USA), Johna Norton (Executive Vice President, Global Quality), Diogo Rau (Executive Vice President and Chief Information and Digital Officer), Daniel Skovronsky, M.D., Ph.D. (Executive Vice President, Chief Scientific Officer and President, Lilly Research Laboratories and Lilly Immunology), Jacob Van Naarden (Executive Vice President and President, Loxo@Lilly), Alonzo Weems (Executive Vice President, Enterprise Risk Management, and Chief Ethics and Compliance Officer), Anne White (Executive Vice President and President, Lilly Neuroscience), Ilya Yuffa (Executive Vice President and President, Lilly International)

• Annual Revenue: $34.1 billion (FY2023)
• Net Income: $5.2 billion (FY2023)
• Market Cap: $398.3 billion (as of Q2 2023)
• Total Assets: $64.0 billion (FY2023)
• Number of employees: 43,000 (as of December 31, 2023)
• Key Financial Highlights: Revenue increased 20% year-over-year, driven by volume growth and higher realized prices, primarily from key products like Mounjaro, Verzenio, and Jardiance. Net income decreased 16% year-over-year, primarily due to increased R&D expenses and higher acquired in-process research and development charges.

Eli Lilly and Company develops and markets a range of pharmaceutical products across various therapeutic areas.

• Diabetes, Obesity, and Other Cardiometabolic Products: Includes incretin-based therapies like Trulicity and Mounjaro, SGLT2 inhibitors such as Jardiance, and various insulin products like Humalog and Humulin.
• Oncology Products: Offers cancer therapies such as Verzenio, Cyramza, Erbitux, Tyvyt, and Alimta.
• Immunology Products: Includes Taltz and Olumiant for conditions like psoriasis, rheumatoid arthritis, and atopic dermatitis.
• Neuroscience Products: Offers medications for conditions like migraine and depression, including Emgality and Cymbalta.
• Other Products and Therapies: Includes treatments for osteoporosis (Forteo) and erectile dysfunction (Cialis).

Eli Lilly and Company operates within a single business segment: human pharmaceutical products.

Eli Lilly and Company's core business strategy revolves around uniting caring with discovery to create medicines that improve lives. The company prioritizes research and development of innovative medicines, both internally and through collaborations and acquisitions. Key strategic initiatives include expanding the value of existing products through new uses and formulations, focusing on therapeutic areas like diabetes, obesity, immunology, neuroscience, and oncology, and maintaining a global presence to address diverse medical needs.

Eli Lilly and Company operates in the highly competitive global pharmaceutical industry. The company faces competition from other large multinational pharmaceutical companies, as well as from generic and biosimilar manufacturers. Key market trends affecting the business include increasing pricing pressures from payers, evolving regulatory landscapes, and a growing demand for innovative therapies with demonstrated cost-effectiveness.

• Research and Development Uncertainty: The pharmaceutical R&D process is inherently risky and expensive, with a high rate of failure. The company may not succeed in developing or acquiring new products to replace revenue from those facing patent expirations or competition.
• Competition: Intense competition from other pharmaceutical companies, including generic and biosimilar manufacturers, can negatively impact sales and market share.
• Pricing and Reimbursement Pressures: Increasing government price controls and restrictions on reimbursement by public and private payers can significantly affect revenue and profitability.
• Product Safety and Efficacy Concerns: Potential safety or efficacy issues with marketed products can lead to product recalls, litigation, and reputational damage.
• Intellectual Property Risks: The company's success depends on protecting its intellectual property. Patent challenges, litigation, or loss of patent protection can severely impact revenue.